Logo image of RCEL

AVITA MEDICAL INC (RCEL) Stock Fundamental Analysis

NASDAQ:RCEL - Nasdaq - US05380C1027 - Common Stock - Currency: USD

9.95  -0.27 (-2.64%)

After market: 9.96 +0.01 (+0.1%)

Fundamental Rating

3

Overall RCEL gets a fundamental rating of 3 out of 10. We evaluated RCEL against 571 industry peers in the Biotechnology industry. RCEL may be in some trouble as it scores bad on both profitability and health. RCEL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCEL had negative earnings in the past year.
In the past year RCEL has reported a negative cash flow from operations.
In the past 5 years RCEL always reported negative net income.
RCEL had a negative operating cash flow in each of the past 5 years.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RCEL has a worse Return On Assets (-77.59%) than 68.21% of its industry peers.
RCEL has a worse Return On Equity (-1374.64%) than 84.72% of its industry peers.
Industry RankSector Rank
ROA -77.59%
ROE -1374.64%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

RCEL has a Gross Margin of 86.60%. This is amongst the best in the industry. RCEL outperforms 90.05% of its industry peers.
In the last couple of years the Gross Margin of RCEL has grown nicely.
RCEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M 25M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

RCEL has an Altman-Z score of -5.20. This is a bad value and indicates that RCEL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.20, RCEL is doing worse than 62.88% of the companies in the same industry.
RCEL has a Debt/Equity ratio of 9.39. This is a high value indicating a heavy dependency on external financing.
RCEL has a worse Debt to Equity ratio (9.39) than 85.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.39
Debt/FCF N/A
Altman-Z -5.2
ROIC/WACCN/A
WACC10.67%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RCEL has a Current Ratio of 2.83. This indicates that RCEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.83, RCEL is doing worse than 68.03% of the companies in the same industry.
A Quick Ratio of 2.47 indicates that RCEL has no problem at all paying its short term obligations.
RCEL has a Quick ratio of 2.47. This is in the lower half of the industry: RCEL underperforms 70.87% of its industry peers.
Industry RankSector Rank
Current Ratio 2.83
Quick Ratio 2.47
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

RCEL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.71%.
RCEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.13%.
Measured over the past years, RCEL shows a very strong growth in Revenue. The Revenue has been growing by 30.02% on average per year.
EPS 1Y (TTM)-70.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.14%
Revenue 1Y (TTM)28.13%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%29.69%

3.2 Future

Based on estimates for the next years, RCEL will show a very strong growth in Earnings Per Share. The EPS will grow by 43.19% on average per year.
The Revenue is expected to grow by 48.78% on average over the next years. This is a very strong growth
EPS Next Y71.22%
EPS Next 2Y39.22%
EPS Next 3Y46.74%
EPS Next 5Y43.19%
Revenue Next Year53.51%
Revenue Next 2Y41.91%
Revenue Next 3Y50.59%
Revenue Next 5Y48.78%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

RCEL's earnings are expected to grow with 46.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.22%
EPS Next 3Y46.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVITA MEDICAL INC

NASDAQ:RCEL (2/20/2025, 8:00:01 PM)

After market: 9.96 +0.01 (+0.1%)

9.95

-0.27 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners24.64%
Inst Owner Change4.91%
Ins Owners0.9%
Ins Owner Change1.46%
Market Cap260.89M
Analysts77.14
Price Target17.14 (72.26%)
Short Float %6.97%
Short Ratio9.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.45%
Min EPS beat(2)-39.31%
Max EPS beat(2)0.41%
EPS beat(4)1
Avg EPS beat(4)-25.93%
Min EPS beat(4)-51.24%
Max EPS beat(4)0.41%
EPS beat(8)3
Avg EPS beat(8)-15.07%
EPS beat(12)7
Avg EPS beat(12)-1.56%
EPS beat(16)10
Avg EPS beat(16)1.72%
Revenue beat(2)0
Avg Revenue beat(2)-7.79%
Min Revenue beat(2)-14.23%
Max Revenue beat(2)-1.35%
Revenue beat(4)1
Avg Revenue beat(4)-3.98%
Min Revenue beat(4)-14.23%
Max Revenue beat(4)1.11%
Revenue beat(8)4
Avg Revenue beat(8)-2.25%
Revenue beat(12)8
Avg Revenue beat(12)3.26%
Revenue beat(16)11
Avg Revenue beat(16)5.86%
PT rev (1m)0%
PT rev (3m)11.84%
EPS NQ rev (1m)-21.33%
EPS NQ rev (3m)-28.53%
EPS NY rev (1m)-8.26%
EPS NY rev (3m)-6.08%
Revenue NQ rev (1m)-9.17%
Revenue NQ rev (3m)-8.32%
Revenue NY rev (1m)-3.55%
Revenue NY rev (3m)0.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.06
P/FCF N/A
P/OCF N/A
P/B 57.99
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS2.45
BVpS0.17
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.59%
ROE -1374.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.6%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 9.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 814.48%
Cap/Sales 14.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.83
Quick Ratio 2.47
Altman-Z -5.2
F-Score3
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.14%
EPS Next Y71.22%
EPS Next 2Y39.22%
EPS Next 3Y46.74%
EPS Next 5Y43.19%
Revenue 1Y (TTM)28.13%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%29.69%
Revenue Next Year53.51%
Revenue Next 2Y41.91%
Revenue Next 3Y50.59%
Revenue Next 5Y48.78%
EBIT growth 1Y-32.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year71.86%
EBIT Next 3Y34.9%
EBIT Next 5Y22.48%
FCF growth 1Y-47.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.75%
OCF growth 3YN/A
OCF growth 5YN/A